Nanostructured lipid carriers based mRNA vaccine leads to a T cell–inflamed tumour microenvironment favourable for improving PD-1/PD-L1 blocking therapy and long-term immunity in a cold tumour model
Carole Fournier(Centre National de la Recherche Scientifique), Patrice N. Marche(Centre National de la Recherche Scientifique)
Cited by 16